Cargando…

310 Ribavirin coupled to hemoglobin protects against viral hepatitis induced by the corona virus MHV-3 in mice

Detalles Bibliográficos
Autores principales:	Levy, Gary A., Ghanekar, Anand, McGilvray, Ian, Ng, Nancy F., Levy, Adam, Fung, Laisum, Phillips, M.J., Biessels, Pieter, Woods, Caroline, Adamson, Gord, Bell, David N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2003
Materias:	AASLD abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131649/ https://www.ncbi.nlm.nih.gov/pubmed/12883474 http://dx.doi.org/10.1016/S0270-9139(03)80353-1

Ejemplares similares

868: PREVENTING HEPATCELLULAR CARCINOMA WITH TENOFOVIR VS ENTECAVIR: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF PROPENSITY SCORE MATCHED STUDIES
por: Tan, Darren J., et al.
Publicado: (2022)

437 A TAILORED PROGRAM FOR SCREENING, IMPROVED ACCESS TO CARE, AND PRIORITIZATION OF TREATMENT FOR PWUD WITH CHRONIC HCV INFECTION.
por: Mangia, Alessandra, et al.
Publicado: (2021)

13 CHEMOPREVENTIVE EFFECT OF STATIN ON HEPATOCELLULAR CARCINOMA IN NON-ALCOHOLIC STEATOHEPATITIS PATIENTS WITH CIRRHOSIS
por: Al-Yaman, Wael A., et al.
Publicado: (2021)

7 A RETROSPECTIVE ANALYSIS OF COVID-19 INFECTED PATIENTS WITH ACUTE LIVER FAILURE IN A SAFETY NET HOSPITAL
por: Pellegrini, James R., et al.
Publicado: (2021)

8 PREDICTORS OF OUTCOMES OF COVID-19 INFECTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
por: Sandhu, Sunny, et al.
Publicado: (2021)

12 MULTIFOCAL INTRAHEPATIC CHOLANGIOCARCINOMA: IMMUNOGENOMIC AND EPIGENOMIC HETEROGENEITIES INFLUENCE THE RESPONSES TO TARGETED THERAPY AND IMMUNOTHERAPY
por: Chen, Shu-Ling, et al.
Publicado: (2021)

9 ELEVATED LIVER ENZYMES PORTENDS A HIGHER RATE OF COMPLICATIONS AND DEATH IN ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
por: Currier, Emily E., et al.
Publicado: (2021)

6 CIRRHOSIS IS ASSOCIATED WITH SIGNIFICANTLY WORSENED CLINICAL OUTCOMES OF COVID-19 INFECTION IN A RETROSPECTIVE ANALYSIS OF 23,474 PATIENTS ACROSS 143 HOSPITALS
por: Hwang, Andrew W., et al.
Publicado: (2021)

435 INCIDENCE AND MORTALITY OF COVID-19 IN POST-LIVER TRANSPLANT PATIENTS IN A LARGE INTEGRATED HEALTHCARE SYSTEM
por: Tien, Andy, et al.
Publicado: (2021)

11 TRENDS IN ALCOHOL RELATED LIVER DISEASE DURING THE SARS-COV 2 PANDEMIC: REAL-TIME ANALYSIS OF SYSTEMWIDE DATA TRENDS USING EPIC SLICERDICER™.
por: Roark, Travis, et al.
Publicado: (2021)

10 IMPACT OF CHRONIC LIVER DISEASE ON THE COVID-19 HOSPITAL ADMITTED PATIENTS
por: Amjad, Waseem, et al.
Publicado: (2021)

Su316 INCREASED DIAGNOSIS OF HEPATOCELLULAR CARCINOMA IN HOSPITALIZED PATIENTS WITH ALCOHOL RELATED HEPATITIS AFTER THE COVID-19 OUTBREAK: A GLOBAL MULTI-CENTER PROPENSITY MATCHED ANALYSIS.
por: Perisetti, Abhilash, et al.
Publicado: (2021)

Su317 CORONAVIRUS DISEASE 2019 AND LIVER INJURY: A RETROSPECTIVE ANALYSIS OF HOSPITALIZED PATIENTS IN NEW YORK CITY
por: Bender, Joshua M., et al.
Publicado: (2021)

Su327 DIAGNOSIS AND CHARACTERISTICS OF IMMUNE CHECKPOINT INHIBITOR-MEDIATED CHOLANGIOPATHY: A CASE SERIES
por: Eyada, Mostafa, et al.
Publicado: (2021)

Su324 THE IMPACT OF THE COVID-19 PANDEMIC ON LIVER BIOMARKERS AND QUALITY OF LIFE IN PATIENTS WITH NAFLD
por: Clarke, Lindsay M., et al.
Publicado: (2021)

Su318 PATTERNS OF LIVER TRANSPLANTATION EVALUATIONS FOR HOSPITALIZED ADULTS WITH ACUTE ALCOHOLIC HEPATITIS DURING COVID-19: A SINGLE CENTER STUDY
por: Bangaru, Saroja, et al.
Publicado: (2021)

Su320 A RETROSPECTIVE ANALYSIS OF OUTCOMES AMONGST COVID-19 PATIENTS WITH ACUTE HEPATITIS RECEIVING N-ACETYLCYSTEINE THERAPY IN A SAFETY NET HOSPITAL
por: Pellegrini, James R., et al.
Publicado: (2021)

Su319 KEY PRO-INFLAMMATORY/INJURY FEATURES OF COVID-19 PATIENTS WITH ALCOHOL USE
por: Rios, Cristian D., et al.
Publicado: (2021)

Su321 DEGREE AND PATTERN OF ELEVATED HEPATOBILIARY ENZYMES ARE PROGNOSTIC OF SEVERE CLINICAL OUTCOMES IN HOSPITALIZED COVID-19 PATIENTS
por: Wagner, Jason, et al.
Publicado: (2021)

Su322 SEVERE CHOLESTATIC HEPATITIS SECONDARY TO SARS-COV-2
por: Lindholm, Christopher R., et al.
Publicado: (2021)

Su326 IS TRANSAMINITIS AN INDEPENDENT RISK FACTOR FOR ALL-CAUSE MORTALITY IN COVID-19?
por: Mughal, Mohsin, et al.
Publicado: (2021)

Su323 THE PATTERNS OF LIVER INJURY IN COVID-19 POSITIVE PREGNANT FEMALES: A CASE SERIES
por: Raju, Sneha, et al.
Publicado: (2021)

Su325 HEPATIC STEATOSIS MAY LEAD TO WORSE OUTCOMES IN PATIENTS WITH LIVER INJURY AND COVID-19
por: Shaikh, Danial H., et al.
Publicado: (2021)

EP1194: THE PROGNOSTIC IMPLICATIONS OF LIVER FUNCTION TEST ABNORMALITIES IN PATIENTS ADMITTED TO HOSPITAL WITH COVID-19
por: Cohen, Jason, et al.
Publicado: (2022)

Tu1255: SAFETY AND EFFICACY OF COVID-19 VACCINES IN PATIENTS WITH CIRRHOSIS: A CROSS SECTIONAL, OBSERVATIONAL STUDY
por: Singh, Virendra, et al.
Publicado: (2022)

EP1192: LIVER TEST ABNORMALITIES IN COVID-19 PATIENTS MAY NOT BE RELATED TO CYTOKINE STORM
por: Piskorz, Maria, et al.
Publicado: (2022)

782: COMPARISON OF INFECTION-INDUCED AND VACCINE-INDUCED IMMUNITY AGAINST CORONAVIRUS 2019 IN PATIENTS WITH CIRRHOSIS
por: John, Binu V., et al.
Publicado: (2022)

781: PATIENTS WITH COMPENSATED CIRRHOSIS AND COVID-19 HAVE A HIGHER SHORT-TERM RATE OF DECOMPENSATION AND MORTALITY BUT THOSE WHO SURVIVE COVID-19 HAVE NO DIFFERENCE IN OUTCOMES AT 1 YEAR: A MULTICENTER RESEARCH NETWORK STUDY
por: Chowdhry, Monica, et al.
Publicado: (2022)

Tu1258: EFFECTIVENESS OF COVID-19 VIRAL VECTOR JANSSEN AD.26.COV2.S VACCINE AND COMPARISON WITH MRNA VACCINES IN CIRRHOSIS
por: John, Binu V., et al.
Publicado: (2022)

EP1195: COVID-19 INFECTION AND BREAKTHROUGH INFECTION IN POST LIVER TRANSPLANT PATIENTS
por: Moein, Hamid-Reza, et al.
Publicado: (2022)

Tu1257: AUTOIMMUNE HEPATITIS FOLLOWING COVID-19 VACCINATION: A SYSTEMATIC REVIEW OF THE LITERATURE
por: Chow, Kenneth W., et al.
Publicado: (2022)

Tu1268: LONGITUDINAL ASSESSMENT OF SEROLOGICAL RESPONSE AFTER THREE DOSES OF SARS-COV-2 MRNA VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Gandle, Cassandra, et al.
Publicado: (2022)

Mo1333: DIFFERENCES IN ACUTE ALCOHOL-RELATED HEALTHCARE UTILIZATION COMPARING BEFORE AND DURING THE COVID-19 PANDEMIC
por: Edwards, Mitchell, et al.
Publicado: (2022)

Sa1389: LESSONS FROM HEPATITIS C TREATMENT DURING THE COVID-19 PANDEMIC: DECREASED RESOURCE UTILIZATION LEADS TO SIMILAR EFFICACY IN BRITISH COLUMBIA, CANADA
por: Jiang, Shirley X., et al.
Publicado: (2022)

Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4)
por: AlEid, Ahmad, et al.
Publicado: (2022)

Tu1261: IMPACT OF THE COVID-19 PANDEMIC ON THE EPIDEMIOLOGY OF ALCOHOL-ASSOCIATED HEPATITIS
por: Frolkis, Alexandra, et al.
Publicado: (2022)

Sa1372: TRACKING CIRRHOSIS CARE DURING COVID-19 PANDEMIC
por: Adejumo, Adeyinka C., et al.
Publicado: (2022)

Tu1266: VARIABLE IMPACT OF COVID-19 PANDEMIC ON HOSPITALIZATION FOR ALCOHOL-ASSOCIATED LIVER DISEASE.
por: Lee, Tai-Ping, et al.
Publicado: (2022)

Tu1256: METFORMIN USE IS ASSOCIATED WITH LESS FREQUENT SEVERE LIVER INJURY UPON HOSPITAL ADMISSIN WITH COVID-19
por: Kuntzen, Christian, et al.
Publicado: (2022)

Tu1254: SARS-COV-2 VACCINATION HESITANCY AND RISK OF DISEASE FLARE ARE BOTH LOW AMONG AN AUTOIMMUNE HEPATITIS PATIENT COHORT
por: Chalasani, Sai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vli5hnsje0ghmuaiqe3qclvr0c